» Articles » PMID: 25004350

Obesity and Age at Diagnosis of Endometrial Cancer

Overview
Journal Obstet Gynecol
Date 2014 Jul 9
PMID 25004350
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Obesity is an established risk factor for development of endometrial cancer. We hypothesized that obesity might also be associated with an earlier age at endometrial cancer diagnosis, because mechanisms that drive the obesity-endometrial cancer association might also accelerate tumorigenesis.

Methods: A retrospective chart review was conducted of all cases of endometrial cancer diagnosed from 1999 to 2009 at a large medical center in New York City. The association of body mass index (BMI) with age at endometrial cancer diagnosis, comorbidities, stage, grade, and radiation treatment was examined using analysis of variance and linear regression. Overall survival by BMI category was assessed using Kaplan-Meier method and the log-rank test.

Results: A total of 985 cases of endometrial cancer were identified. The mean age at endometrial cancer diagnosis was 67.1 years (±11.9 standard deviation) in women with a normal BMI, whereas it was 56.3 years (±10.3 standard deviation) in women with a BMI greater than 50. Age at diagnosis of endometrioid-type cancer decreased linearly with increasing BMI (y=67.89-1.86x, R=0.049, P<.001). This association persisted after multivariable adjustment (R=0.181, P<.02). A linear association between BMI and age of nonendometrioid cancers was not found (P=.12). There were no differences in overall survival by BMI category.

Conclusions: Obesity is associated with earlier age at diagnosis of endometrioid-type endometrial cancers. Similar associations were not, however, observed with nonendometrioid cancers, consistent with different pathways of tumorigenesis.

Level Of Evidence: II.

Citing Articles

HIF1A, EPAS1, and VEGFA: angiogenesis and hypoxia-related gene expression in endometrium and endometrial epithelial tumors.

Englert-Golon M, Toklowicz M, Zbikowska A, Sajdak S, Kotwicka M, Jagodzinski P J Appl Genet. 2025; .

PMID: 39888575 DOI: 10.1007/s13353-025-00939-7.


Lipid metabolism reprogramming in endometrial cancer: biological functions and therapeutic implications.

Wang X, Li Y, Hou X, Li J, Ma X Cell Commun Signal. 2024; 22(1):436.

PMID: 39256811 PMC: 11385155. DOI: 10.1186/s12964-024-01792-7.


The Importance of Metabolic Factors in Endometrial Cancer: Evaluating the Utility of the Triglyceride-to-Glycemia Index and Triglyceride-to-High-Density Lipoprotein Ratio As Biomarkers.

Marin A, Vladareanu R, Petca A, Filipescu A Cureus. 2024; 16(6):e62099.

PMID: 38989325 PMC: 11236432. DOI: 10.7759/cureus.62099.


Endometrial Cancer in Reproductive-Aged Females: Etiology and Pathogenesis.

Bassette E, Ducie J Biomedicines. 2024; 12(4).

PMID: 38672240 PMC: 11047839. DOI: 10.3390/biomedicines12040886.


Sonographic, Demographic, and Clinical Characteristics of Pre- and Postmenopausal Women with Endometrial Cancer; Results from a Post Hoc Analysis of the IETA4 (International Endometrial Tumor Analysis) Multicenter Cohort.

Green R, Fischerova D, Testa A, Franchi D, Fruhauf F, Lindqvist P Diagnostics (Basel). 2024; 14(1).

PMID: 38201310 PMC: 10802150. DOI: 10.3390/diagnostics14010001.